Quell Therapeutics' CEO describes the process of using genetically modified Tregs for immune dysregulation conditions

blonca9
Apr 29, 2024
1 min read

Iain McGill discusses the company's clinical stage liver transplant program, as well as the IBD and type 1 diabetes programs that earned Quell a partnership with AstraZeneca.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Quell Therapeutics' CEO describes the process of using genetically modified Tregs for immune dysregulation conditions

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight